Legislators introduce bill to reverse CMS decision on ESA coverage

Article

Battle over ESA coverage continues

Federal lawmakers are presenting a united front in their battle to save Medicare reimbursements for anemia drugs. Reps. Anna Eshoo (D, Calif.) and Mike Rogers (R, Mich.) have introduced a bill to reverse a CMS decision to restrict reimbursements to low-dose levels of erythropoiesis-stimulating agents (ESAs). Thedecision, issued in July, limits the duration of ESA treatment to a maximum of eight weeks after a chemotherapy session and requires doctors to wait until hemoglobin levels drop below 10 gm/dl before starting ESA treatment. The restrictions have come under fire from several groups, including the

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Related Content
© 2025 MJH Life Sciences

All rights reserved.